-
公开(公告)号：US20190275068A1
公开(公告)日：2019-09-12
申请号：US16463786
申请日：2017-11-17
发明人： Juan Carlos MORALES SÁNCHEZ , Pablo PEÑALVER PUENTE , Francisco Javier DÍAZ CORRALES , María Lourdes VALDÉS SÁNCHEZ , Ana Belén GARCÍA DELGADO , Adoración MONTERO SÁNCHEZ
IPC分类号： A61K31/7034 , A61P27/02 , A61K47/40
摘要： The present invention relates to the therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration.
-
公开(公告)号：US10369175B2
公开(公告)日：2019-08-06
申请号：US16028325
申请日：2018-07-05
发明人： Thomas Julius Borody
IPC分类号： A61K45/00 , A01N63/00 , A61M36/14 , A61K9/16 , A61K9/50 , A61K35/742 , A61K35/74 , A61K38/48 , A61K35/741 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K9/19 , A61K35/37 , A61K31/545 , A61K39/00 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K39/39 , A61K51/12 , A61K35/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
公开(公告)号：US10369114B2
公开(公告)日：2019-08-06
申请号：US15603992
申请日：2017-05-24
IPC分类号： A61K9/51 , A61K31/7034 , A61K31/713 , A61K31/12 , A61K31/137 , A61K31/19 , A61K38/14 , A61K38/28 , A61K45/06 , A61K39/29 , A61K39/395 , A61K31/546 , A61K9/127
摘要： The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
-
公开(公告)号：US10300083B2
公开(公告)日：2019-05-28
申请号：US15383625
申请日：2016-12-19
IPC分类号： A01N43/04 , A61K31/70 , A61K31/7028 , A61K31/7008 , A61K31/7034 , A61K31/7024 , A61K31/351
摘要： The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
-
公开(公告)号：US10295536B2
公开(公告)日：2019-05-21
申请号：US14249814
申请日：2014-04-10
申请人： TECHLAB, INC.
IPC分类号： G01N33/569 , A61K35/74 , A61K45/06 , A61K38/14 , A61K31/4164 , A61K31/7034
摘要： Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.
-
公开(公告)号：US20190085007A1
公开(公告)日：2019-03-21
申请号：US15951277
申请日：2018-04-12
申请人： Thanares GmbH
发明人： Hans-Michael THIEDE , Wolfgang KEHR
IPC分类号： C07H15/203 , A61K31/7034 , A61K9/28 , A61K9/00
摘要： The invention relates to phenoxy derivatives with glycosidically bound sugar moieties, pharmaceutical compositions containing such compounds, uses of such compounds and compositions, and methods of making such compounds and pharmaceutical compositions.
-
公开(公告)号：US20190076362A1
公开(公告)日：2019-03-14
申请号：US16184575
申请日：2018-11-08
发明人： Salim Shah
IPC分类号： A61K9/20 , A61K31/44 , A61P9/04 , A61K31/7034 , A61K31/585 , A61P9/12
CPC分类号： A61K9/2054 , A61K9/2013 , A61K9/2018 , A61K31/44 , A61K31/585 , A61K31/64 , A61K31/7034 , A61K45/06 , A61P9/04 , A61P9/12 , A61K2300/00
摘要： Disclosed herein are treatments for diseases such as hypertension, diabetes, and congestive heart failure using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.
-
78.发明申请公开(公告)号：US20190060339A1
公开(公告)日：2019-02-28
申请号：US16081275
申请日：2017-03-01
申请人： GlycoMimetics, Inc.
IPC分类号： A61K31/7034 , A61K31/765 , A61P9/10
摘要： New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.
-
公开(公告)号：US20190022029A1
公开(公告)日：2019-01-24
申请号：US16058437
申请日：2018-08-08
申请人： BioMendics, LLC
IPC分类号： A61K31/05 , A61K8/67 , A61K9/00 , A61K8/60 , A61K8/33 , A61K8/34 , A61Q7/00 , A61Q19/08 , A61K47/40 , A61K47/36 , A61K9/06 , A61K45/06 , A61K31/7034 , A61K31/09 , A61K31/085 , A61K8/73 , A61K9/08 , A61K9/19 , A61K8/70 , A61K31/03 , A61K31/167 , A61K31/375 , A61K31/655
CPC分类号： A61K31/05 , A61K8/33 , A61K8/347 , A61K8/602 , A61K8/676 , A61K8/70 , A61K8/733 , A61K8/738 , A61K9/0019 , A61K9/06 , A61K9/08 , A61K9/19 , A61K31/03 , A61K31/085 , A61K31/09 , A61K31/167 , A61K31/375 , A61K31/655 , A61K31/7034 , A61K45/06 , A61K47/36 , A61K47/40 , A61Q7/00 , A61Q19/08 , Y02A50/401 , A61K2300/00
摘要： Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CRa═CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.
-
公开(公告)号：US20190015437A1
公开(公告)日：2019-01-17
申请号：US15918477
申请日：2018-03-12
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z.I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K31/522 , A61K31/155 , A61K31/7034 , A61K45/06 , A61K9/28 , A61K9/20
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
-
-
-
-
-
-
-
-
搜索结果
1547 条记录 (耗时 0.039 秒)
